News

High-performing teams and individuals honoured at DMTC Awards

Research with real-world impact, efforts to build the capacity of Australia’s small businesses and breakthroughs in technology development have been recognised with Awards for Excellence at the DMTC Annual Conference for 2024.

Awardees were honoured in seven categories, with each demonstrating commitment to excellence and collaboration across a diverse portfolio of programs and projects. (more…)

Well-deserved recognition for vaccine collaboration leader

The CEO of Australian biotech company Sementis Limited, Dr Anne Collins, has been honoured with the Collaboration Award at the DMTC Annual Conference for 2024.

Often described as the MVP Award, the Collaboration Award honours a leader who embodies the spirit of collaboration that is integral to DMTC’s strategic intent and outlook.

(more…)

Sovereign Capability at Scale

A national team of experts will advance an innovative biopolymer particle-based platform technology to develop vaccine candidates to protect against biowarfare threats including Q Fever, tularaemia, and melioidosis.

Health Security Systems Australia (HSSA) is engaging with leading scientific experts from across Australia, led by Griffith University, including the Australian Rickettsial Reference Laboratory in Geelong, the NSW Department of Primary Industries, the University of Western Australia, and industry partner BioCina Pty Ltd, an Australian-based global biologics Contract Development Manufacturing Organisation (CDMO). (more…)

Pushing back against viruses with pandemic potential

Health Security Systems Australia (HSSA) is working with experts at the University of Melbourne at the Peter Doherty Institute for Infection and Immunity (Doherty Institute), The University of Queensland’s National Biologics Facility, and industry partner Biointelect Pty Ltd to develop a novel therapeutic platform technology to combat multiple viral pathogens with pandemic potential. (more…)